CITIUS PHARMACEUTICALS INC (CTXR) Fundamental Analysis & Valuation

NASDAQ:CTXR • US17322U3068

Current stock price

0.86 USD
+0.02 (+2.38%)
Last:

This CTXR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CTXR Profitability Analysis

1.1 Basic Checks

  • In the past year CTXR has reported negative net income.
  • CTXR had a negative operating cash flow in the past year.
  • CTXR had negative earnings in each of the past 5 years.
  • CTXR had a negative operating cash flow in each of the past 5 years.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • CTXR's Return On Assets of -25.56% is in line compared to the rest of the industry. CTXR outperforms 56.02% of its industry peers.
  • The Return On Equity of CTXR (-44.88%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -25.56%
ROE -44.88%
ROIC N/A
ROA(3y)-31.85%
ROA(5y)-28.46%
ROE(3y)-49.95%
ROE(5y)-40.22%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • CTXR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CTXR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CTXR has more shares outstanding
  • The number of shares outstanding for CTXR has been reduced compared to 5 years ago.
  • Compared to 1 year ago, CTXR has a worse debt to assets ratio.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • CTXR has an Altman-Z score of -3.13. This is a bad value and indicates that CTXR is not financially healthy and even has some risk of bankruptcy.
  • CTXR's Altman-Z score of -3.13 is on the low side compared to the rest of the industry. CTXR is outperformed by 62.83% of its industry peers.
  • A Debt/Equity ratio of 0.01 indicates that CTXR is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.01, CTXR is in line with its industry, outperforming 54.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.13
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 0.99 indicates that CTXR may have some problems paying its short term obligations.
  • CTXR's Current ratio of 0.99 is on the low side compared to the rest of the industry. CTXR is outperformed by 87.43% of its industry peers.
  • A Quick Ratio of 0.40 indicates that CTXR may have some problems paying its short term obligations.
  • CTXR's Quick ratio of 0.40 is on the low side compared to the rest of the industry. CTXR is outperformed by 92.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.4
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CTXR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.99% over the past year.
EPS 1Y (TTM)29.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.32% on average over the next years. This is a very strong growth
  • CTXR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 112.22% yearly.
EPS Next Y141.4%
EPS Next 2Y64.19%
EPS Next 3Y37.83%
EPS Next 5Y22.32%
Revenue Next Year731.6%
Revenue Next 2Y353.74%
Revenue Next 3Y213.93%
Revenue Next 5Y112.22%

3.3 Evolution

CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

4

4. CTXR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CTXR. In the last year negative earnings were reported.
  • CTXR is valuated cheaply with a Price/Forward Earnings ratio of 0.30.
  • Based on the Price/Forward Earnings ratio, CTXR is valued cheaper than 100.00% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CTXR to the average of the S&P500 Index (38.00), we can say CTXR is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.3
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CTXR's earnings are expected to grow with 37.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y64.19%
EPS Next 3Y37.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTXR Dividend Analysis

5.1 Amount

  • No dividends for CTXR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTXR Fundamentals: All Metrics, Ratios and Statistics

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (4/22/2026, 10:37:35 AM)

0.86

+0.02 (+2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)05-12
Inst Owners7.66%
Inst Owner Change0%
Ins Owners2.2%
Ins Owner Change0%
Market Cap19.25M
Revenue(TTM)3.94M
Net Income(TTM)-35.89M
Analysts80
Price Target5.1 (493.02%)
Short Float %17.85%
Short Ratio6.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-44.04%
Min Revenue beat(2)-100%
Max Revenue beat(2)11.92%
Revenue beat(4)1
Avg Revenue beat(4)-72.02%
Min Revenue beat(4)-100%
Max Revenue beat(4)11.92%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.3
P/S 4.88
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.09
EYN/A
EPS(NY)2.85
Fwd EY330.91%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS0.18
BVpS3.57
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -25.56%
ROE -44.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.85%
ROA(5y)-28.46%
ROE(3y)-49.95%
ROE(5y)-40.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.4
Altman-Z -3.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.66%
EPS Next Y141.4%
EPS Next 2Y64.19%
EPS Next 3Y37.83%
EPS Next 5Y22.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year731.6%
Revenue Next 2Y353.74%
Revenue Next 3Y213.93%
Revenue Next 5Y112.22%
EBIT growth 1Y12.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.68%
OCF growth 3YN/A
OCF growth 5YN/A

CITIUS PHARMACEUTICALS INC / CTXR Fundamental Analysis FAQ

What is the fundamental rating for CTXR stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTXR.


What is the valuation status of CITIUS PHARMACEUTICALS INC (CTXR) stock?

ChartMill assigns a valuation rating of 4 / 10 to CITIUS PHARMACEUTICALS INC (CTXR). This can be considered as Fairly Valued.


What is the profitability of CTXR stock?

CITIUS PHARMACEUTICALS INC (CTXR) has a profitability rating of 1 / 10.


What is the expected EPS growth for CITIUS PHARMACEUTICALS INC (CTXR) stock?

The Earnings per Share (EPS) of CITIUS PHARMACEUTICALS INC (CTXR) is expected to grow by 141.4% in the next year.